Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05220722 · ClinicalTrials.gov registry record · Phase 1
Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors
A Phase 1 study, sponsored by TriSalus Life Sciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT05220722 is a Phase 1 study that was terminated before completion, run by TriSalus Life Sciences. The registered enrollment target is 23 participants.
The verdict
NCT05220722, a Phase 1 study, was terminated before completion, sponsored by TriSalus Life Sciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
This is an Open-label, Phase 1b/2 Study of the Pressure-Enabled Hepatic Artery Infusion (HAI) of SD-101, a TLR9 agonist, Alone or in Combination with Intravenous Checkpoint Blockade in Adults with Hepatocellular Carcinoma (HCC) and Intrahepatic Cholangiocarcinoma (ICC).
Interventions
- BIOLOGICAL Pembrolizumab
- BIOLOGICAL Nivolumab
- BIOLOGICAL Ipilimumab
- DRUG SD-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2022-03-02 |
| Est. Completion | 2024-07-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05220722
The ClinicalTrials.gov registry entry for NCT05220722 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TriSalus Life Sciences, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT05220722 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05220722 about?
NCT05220722 is a clinical study titled "Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors". This is an Open-label, Phase 1b/2 Study of the Pressure-Enabled Hepatic Artery Infusion (HAI) of SD-101, a TLR9 agonist, Alone or in Combination with Intravenous Checkpoint Blockade in Adults with Hepatocellular Carcinoma (HCC) and Intrahepatic Cholangiocarcinoma (ICC).
What is the current status of trial NCT05220722?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2022-03-02. Estimated completion is 2024-07-31.
What interventions are being tested in trial NCT05220722?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Nivolumab (BIOLOGICAL), Ipilimumab (BIOLOGICAL), SD-101 (DRUG).
Who is sponsoring clinical trial NCT05220722?
This trial is sponsored by TriSalus Life Sciences, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.